ALKS

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +0.41
Percentage change 1.22	%

Peers: AMGN LLY MRK JNJ PFE BIIB BMY VRTX GILD REGN

| Held by: IJR VTI IWM VB CALF VXF XBI VBK AVUV SPSM

Index	RUT	P/E	15.61	EPS (ttm)	2.18	Insider Own	2.57%	Shs Outstand	162.18M	Perf Week	-0.93%
Market Cap	5.53B	Forward P/E	18.22	EPS next Y	1.87	Insider Trans	-12.91%	Shs Float	158.43M	Perf Month	1.58%
Income	367.07M	PEG	-	EPS next Q	0.29	Inst Own	102.82%	Short Float	8.84%	Perf Quarter	11.21%
Sales	1.56B	P/S	3.55	EPS this Y	-37.03%	Inst Trans	-6.63%	Short Ratio	8.15	Perf Half Y	28.08%
Book/sh	9.03	P/B	3.77	EPS next Y	2.63%	ROA	17.76%	Short Interest	14.01M	Perf Year	19.53%
Cash/sh	4.62	P/C	7.36	EPS next 5Y	-16.31%	ROE	27.90%	52W Range	22.90 - 36.45	Perf YTD	18.32%
Dividend Est.	-	P/FCF	13.64	EPS past 5Y	-	ROI	23.92%	52W High	-6.64%	Beta	0.38
Dividend TTM	-	Quick Ratio	2.65	Sales past 5Y	7.94%	Gross Margin	83.81%	52W Low	48.60%	ATR (14)	1.07
Dividend Ex-Date	-	Current Ratio	3.04	EPS Y/Y TTM	4.57%	Oper. Margin	27.00%	RSI (14)	51.47	Volatility	3.72% 3.26%
Employees	1800	Debt/Eq	0.05	Sales Y/Y TTM	-6.36%	Profit Margin	23.57%	Recom	1.79	Target Price	38.64
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	32.69%	Payout	0.00%	Rel Volume	1.04	Prev Close	33.62
Sales Surprise	13.34%	EPS Surprise	38.27%	Sales Q/Q	13.91%	Earnings	Feb 12 BMO	Avg Volume	1.72M	Price	34.03
SMA20	-2.27%	SMA50	5.57%	SMA200	19.67%	Trades		Volume	1,780,005	Change	1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform	$40
Mar-04-25	Upgrade	UBS	Sell → Neutral	$21 → $38
Feb-11-25	Initiated	Deutsche Bank	Buy	$40
Nov-05-24	Upgrade	Stifel	Hold → Buy	$25 → $36
Jun-17-24	Initiated	TD Cowen	Buy	$34
Mar-19-24	Initiated	Robert W. Baird	Outperform	$37
Feb-20-24	Downgrade	UBS	Neutral → Sell	$25
Nov-20-23	Resumed	JP Morgan	Neutral	$33
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral	$31
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25
Aug-16-22	Initiated	Piper Sandler	Neutral	$26
Apr-22-22	Resumed	Goldman	Buy	$35
Apr-20-22	Initiated	Goldman	Buy	$35
Jan-27-22	Upgrade	Cantor Fitzgerald	Hold → Overweight	$32
Dec-01-21	Initiated	Citigroup	Neutral	$22
Oct-07-21	Upgrade	Jefferies	Hold → Buy	$36
Sep-02-21	Downgrade	BofA Securities	Neutral → Underperform	$27
Oct-15-20	Upgrade	Mizuho	Neutral → Buy	$19 → $24

Show Previous Ratings

Mar-14-25 11:30AM	Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? (Zacks)
11:28AM	The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks (Investor's Business Daily)
10:54AM	Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment? (Insider Monkey)
Mar-01-25 03:25PM	Alkermes plc (ALKS): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-26-25 04:00PM	Alkermes to Participate in Upcoming Investor Conferences (PR Newswire)
02:06AM	Loading…
Feb-13-25 02:06AM	Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Debt-Free Milestone (GuruFocus.com) +7.46%
Feb-12-25 09:30AM	Alkermes (ALKS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:40AM	Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:54AM	Alkermes: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 (PR Newswire)
Feb-11-25 07:23AM	Earnings To Watch: Alkermes PLC (ALKS) Reports Q4 2024 Result (GuruFocus.com)
Feb-10-25 09:16AM	What Analyst Projections for Key Metrics Reveal About Alkermes (ALKS) Q4 Earnings (Zacks)
03:00AM	Are orexins the next golden child of neuroscience? (Pharma Voice)
Feb-05-25 04:00PM	Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025 (PR Newswire)
Jan-13-25 12:48PM	Oneras validation trial of home polysomnography sleep device succeeds (Clinical Trials Arena)
04:00PM	Loading…
Jan-02-25 04:00PM	Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-26-24 12:38PM	Axsome Therapeutics eyes approval after Phase III narcolepsy win (Clinical Trials Arena)
Nov-25-24 04:00PM	Alkermes to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-21-24 08:46AM	Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock? (Zacks)
Nov-11-24 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (PR Newswire)
Nov-07-24 07:00AM	Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences (PR Newswire)
Oct-25-24 03:07AM	Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ... (GuruFocus.com)
Oct-24-24 11:00AM	Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:10AM	Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates (Zacks)
07:10AM	Alkermes: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-23-24 09:05AM	Alkermes PLC (ALKS) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
Oct-22-24 09:15AM	Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
Oct-17-24 04:00PM	Alkermes to Report Third Quarter Financial Results on October 24, 2024 (PR Newswire)
Oct-14-24 04:13PM	Alkermes Stock Jumps Nearly 30% In 3 Months After Hefty Profits (Investor's Business Daily)
01:04PM	Loading…
Oct-12-24 01:04PM	Is Alkermes (ALKS) The Most Undervalued Quality Stock To Buy According To Analysts? (Insider Monkey)
Oct-11-24 09:50AM	Here's Why Alkermes (ALKS) is a Strong Momentum Stock (Zacks) +5.63%
Oct-10-24 09:45AM	Here's Why Alkermes (ALKS) is a Strong Growth Stock (Zacks)
Sep-25-24 08:00AM	Alkermes to Host Investor Event to Review Orexin Portfolio Strategy (PR Newswire)
Sep-23-24 09:45AM	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term (Zacks)
07:00AM	Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 (PR Newswire)
Sep-20-24 09:40AM	Here's Why Alkermes (ALKS) is a Strong Value Stock (Zacks)
Sep-19-24 04:00PM	Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference (PR Newswire)
Sep-13-24 07:00AM	Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards Program (PR Newswire)
Sep-05-24 09:45AM	Here's Why Alkermes (ALKS) is a Strong Growth Stock (Zacks)
Sep-04-24 09:40AM	Why Alkermes (ALKS) is a Top Value Stock for the Long-Term (Zacks)
Aug-28-24 04:00PM	Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-23-24 11:30AM	Alkermes (ALKS) Down 0.2% Since Last Earnings Report: Can It Rebound? (Zacks)
11:12AM	Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680 (Zacks)
04:52AM	Alkermes launches Phase II trial of ALKS 2680 for narcolepsy type 2 (Clinical Trials Arena)
Aug-22-24 07:00AM	Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 (PR Newswire)
Aug-20-24 09:45AM	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term (Zacks)
Aug-19-24 09:40AM	Here's Why Alkermes (ALKS) is a Strong Value Stock (Zacks)
Aug-16-24 09:50AM	Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-01-24 09:45AM	Here's Why Alkermes (ALKS) is a Strong Growth Stock (Zacks)
Jul-30-24 09:40AM	Why Alkermes (ALKS) is a Top Value Stock for the Long-Term (Zacks)
Jul-25-24 10:44AM	Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat (Zacks) +5.77%
Jul-24-24 09:30AM	Alkermes (ALKS) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +6.04%
08:15AM	Alkermes (ALKS) Lags Q2 Earnings Estimates (Zacks)
07:21AM	Alkermes: Q2 Earnings Snapshot (Associated Press Finance)
07:18AM	Alkermes Reiterates FY24 Revenue Outlook - Update (RTT News)
07:00AM	Alkermes plc Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-17-24 04:00PM	Alkermes to Report Second Quarter Financial Results on July 24, 2024 (PR Newswire)
10:01AM	Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Jun-04-24 08:30AM	Alkermes impresses in full-throttle narcolepsy race with Takeda (FierceBiotech.com)
Jun-03-24 07:00AM	Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024 (PR Newswire)
May-31-24 11:31AM	Why Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report? (Zacks)
May-29-24 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (PR Newswire)
May-28-24 07:00AM	Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 (PR Newswire)
May-25-24 12:00PM	3 Biotech Stocks That Could Be Millionaire-Makers: May Edition (InvestorPlace)
May-21-24 08:48AM	Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't? (Zacks)
May-14-24 07:00AM	Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences (PR Newswire)
May-02-24 11:39AM	Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
11:15AM	UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating (MT Newswires)
07:00AM	Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk (PR Newswire)
May-01-24 11:54AM	ALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
11:07AM	Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:36AM	Alkermes's Q1 Earnings, Revenue Grow But Miss Street View (MT Newswires)
09:30AM	Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:30AM	Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates (Zacks)
07:26AM	Alkermes: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-30-24 08:00AM	How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits? (Investor's Business Daily)
Apr-24-24 07:00AM	Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 (PR Newswire)
Apr-22-24 02:14PM	Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition? (Zacks)
Apr-17-24 04:00PM	Alkermes to Report First Quarter Financial Results on May 1, 2024 (PR Newswire)
10:01AM	Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
Apr-11-24 10:15AM	Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study (Zacks)
10:00AM	Alkermes' Innovations Are Transforming Mental Health Treatments (GuruFocus.com)
Apr-10-24 09:45AM	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term (Zacks)
Apr-09-24 12:38PM	BlackBerry, Alkermes rise; Neogen, Tilray Brands fall, Tuesday, 4/9/2024 (Associated Press Finance)
07:00AM	Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia (PR Newswire)
Apr-08-24 07:00AM	Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society (PR Newswire)
Apr-02-24 12:10PM	Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again (Zacks)
Mar-18-24 07:01PM	Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS) (GuruFocus.com)
Mar-15-24 06:15PM	Alkermes (ALKS) Stock Moves -0.45%: What You Should Know (Zacks)
Mar-13-24 12:45PM	3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock (Zacks)
Mar-12-24 09:50AM	Here's Why Alkermes (ALKS) is a Strong Momentum Stock (Zacks)
Mar-10-24 10:00AM	10 Alternatives to Antidepressant Medications (Insider Monkey)
Mar-08-24 09:45AM	Here's Why Alkermes (ALKS) is a Strong Growth Stock (Zacks)
Mar-07-24 06:15PM	Why Alkermes (ALKS) Outpaced the Stock Market Today (Zacks)
07:00AM	Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors (PR Newswire)
Feb-29-24 06:15PM	Alkermes (ALKS) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Feb-23-24 09:50AM	Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term (Zacks)
Feb-21-24 09:45AM	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term (Zacks)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 28 '25	Sale	34.00	1,938	65,892	7,717	Feb 28 05:19 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 25 '25	Sale	35.26	3,743	131,978	7,717	Feb 25 06:38 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 20 '25	Sale	35.69	1,327	47,361	7,717	Feb 20 05:18 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 13 '25	Option Exercise	30.12	144,419	4,350,097	202,294	Feb 14 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 12 '25	Option Exercise	19.64	199,196	3,912,871	262,796	Feb 14 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 12 '25	Sale	32.78	204,921	6,718,278	57,875	Feb 14 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 13 '25	Sale	35.53	144,419	5,130,698	57,875	Feb 14 05:12 PM
Hopkinson Craig C.	Officer	Feb 13 '25	Proposed Sale	35.53	144,419	5,130,694		Feb 13 04:36 PM
Hopkinson Craig C.	Officer	Feb 12 '25	Proposed Sale	32.78	204,921	6,718,276		Feb 12 04:19 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 30 '25	Option Exercise	22.22	97,632	2,169,137	145,208	Jan 31 08:42 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 30 '25	Sale	32.05	100,918	3,234,382	44,290	Jan 31 08:42 PM
Hopkinson Craig C.	Officer	Jan 30 '25	Proposed Sale	32.05	100,918	3,234,380		Jan 30 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 09 '24	Option Exercise	22.70	48,997	1,112,259	108,727	Dec 09 08:53 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 09 '24	Sale	32.07	61,151	1,961,406	47,576	Dec 09 08:53 PM
LAURENCIN CATO T	Director	Dec 09 '24	Option Exercise	22.52	2,691	60,601	25,704	Dec 09 08:51 PM
LAURENCIN CATO T	Director	Dec 09 '24	Sale	31.85	2,691	85,708	23,013	Dec 09 08:51 PM
LAURENCIN CATO T	Director	Dec 09 '24	Proposed Sale	31.85	2,691	85,708		Dec 09 05:27 PM
Hopkinson Craig C.	Officer	Dec 09 '24	Proposed Sale	32.07	61,151	1,961,404		Dec 09 05:24 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 05 '24	Sale	31.50	9,221	290,462	59,730	Dec 05 06:01 PM
Hopkinson Craig C.	Officer	Dec 05 '24	Proposed Sale	31.50	9,221	290,462		Dec 05 04:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 04 '24	Sale	30.77	14,349	441,550	68,951	Dec 04 04:52 PM
Hopkinson Craig C.	Officer	Dec 04 '24	Proposed Sale	30.77	14,349	441,550		Dec 04 04:19 PM
Nichols Christian Todd	Officer	Nov 27 '24	Proposed Sale	29.15	5,208	151,813		Nov 27 04:33 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Nov 27 '24	Sale	29.15	5,208	151,813	60,703	Nov 27 04:22 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 11 '24	Option Exercise	20.03	43,058	862,452	142,296	Nov 12 04:48 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 11 '24	Sale	30.08	58,996	1,774,576	83,300	Nov 12 04:48 PM
Hopkinson Craig C.	Officer	Nov 11 '24	Proposed Sale	30.08	58,996	1,774,578		Nov 12 04:15 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 06 '24	Sale	29.53	10,471	309,169	99,238	Nov 06 07:47 PM
Hopkinson Craig C.	Officer	Nov 06 '24	Proposed Sale	29.53	10,471	309,169		Nov 06 04:33 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Mar 18 '24	Sale	28.10	10,417	292,740	65,911	Mar 18 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Alkermes plc

Upgrade your FINVIZ experience